相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Management of Immunotherapy-Related Toxicities, Version 1.2022
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database
Maria Antonietta Barbieri et al.
FRONTIERS IN ONCOLOGY (2022)
Osimertinib-induced lymphocytopenia and pneumocystis jirovecii pneumonia
H. Takechi et al.
PULMONOLOGY (2022)
QIM21-090: The Expanding Role of an Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events
Kai-li Liang et al.
Journal of the National Comprehensive Cancer Network (2021)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R. Brahmer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections
Minya Lu et al.
THORACIC CANCER (2020)
Opportunistic infections complicating immunotherapy for non-small cell lung cancer
Liu Ziwei et al.
THORACIC CANCER (2020)
NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis
Lise Lurienne et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Adjuvant and Neoadjuvant Immunotherapy in Non - small Cell Lung Cancer
Stephen R. Broderick
THORACIC SURGERY CLINICS (2020)
The efficacy and safety of osimertinib in treating nonsmall cell lung cancer A PRISMA-compliant systematic review and meta-analysis
Jing Liu et al.
MEDICINE (2020)
Infectious complications in patients treated with immune checkpoint inhibitors
Jean-Denis Karam et al.
EUROPEAN JOURNAL OF CANCER (2020)
Association of immune checkpoint inhibitors with respiratory infections: A review
Ryosuke Hamashima et al.
CANCER TREATMENT REVIEWS (2020)
Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab
Kageaki Taima et al.
RESPIROLOGY CASE REPORTS (2020)
A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events
Jarushka Naidoo et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy
Kohei Fujita et al.
RESPIRATORY MEDICINE (2019)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab
Naohiro Uchida et al.
RESPIROLOGY CASE REPORTS (2018)
The biology and management of non-small cell lung cancer
Roy S. Herbst et al.
NATURE (2018)
Aspergillus fumigatus Cell Wall α-(1,3)-Glucan Stimulates Regulatory T-Cell Polarization by Inducing PD-L1 Expression on Human Dendritic Cells
Emmanuel Stephen-Victor et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population
Laura J. Avino et al.
ANNALS OF PHARMACOTHERAPY (2016)
The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma
Maria Del Castillo et al.
CLINICAL INFECTIOUS DISEASES (2016)
Opportunistic infections in patients treated with immunotherapy for cancer
Chrisann Kyi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Risk factors for bacterial pneumonia after cytotoxic chemotherapy in advanced lung cancer patients
Jeong-Ok Lee et al.
LUNG CANCER (2008)
分享论文
